Cargando…
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
BACKGROUND: Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels. There a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179003/ https://www.ncbi.nlm.nih.gov/pubmed/32321460 http://dx.doi.org/10.1186/s12885-020-06770-z |